PubMed:32676695
Annnotations
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 114-122 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T2 | 125-134 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T3 | 224-232 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T4 | 235-244 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T5 | 429-431 | Disease | denotes | RD | http://purl.obolibrary.org/obo/MONDO_0009973 |
T6 | 501-509 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T7 | 601-603 | Disease | denotes | RD | http://purl.obolibrary.org/obo/MONDO_0009973 |
T8 | 823-825 | Disease | denotes | RD | http://purl.obolibrary.org/obo/MONDO_0009973 |
T9 | 984-986 | Disease | denotes | RD | http://purl.obolibrary.org/obo/MONDO_0009973 |
T10 | 1480-1490 | Disease | denotes | arrhythmia | http://purl.obolibrary.org/obo/MONDO_0007263 |
T11 | 1662-1673 | Disease | denotes | arrhythmias | http://purl.obolibrary.org/obo/MONDO_0007263 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 315-324 | http://purl.obolibrary.org/obo/BFO_0000030 | denotes | OBJECTIVE |
T2 | 429-431 | http://purl.obolibrary.org/obo/CLO_0008770 | denotes | RD |
T3 | 601-603 | http://purl.obolibrary.org/obo/CLO_0008770 | denotes | RD |
T4 | 823-825 | http://purl.obolibrary.org/obo/CLO_0008770 | denotes | RD |
T5 | 832-834 | http://purl.obolibrary.org/obo/CLO_0001407 | denotes | 52 |
T6 | 865-866 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T7 | 975-977 | http://purl.obolibrary.org/obo/CLO_0007874 | denotes | ms |
T8 | 984-986 | http://purl.obolibrary.org/obo/CLO_0008770 | denotes | RD |
T9 | 1013-1015 | http://purl.obolibrary.org/obo/CLO_0007874 | denotes | ms |
T10 | 1080-1081 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T11 | 1092-1094 | http://purl.obolibrary.org/obo/CLO_0007874 | denotes | ms |
T12 | 1129-1130 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T13 | 1141-1143 | http://purl.obolibrary.org/obo/CLO_0007874 | denotes | ms |
T14 | 1210-1212 | http://purl.obolibrary.org/obo/CLO_0007874 | denotes | ms |
T15 | 1217-1223 | http://purl.obolibrary.org/obo/UBERON_0003100 | denotes | female |
T16 | 1234-1236 | http://purl.obolibrary.org/obo/CLO_0007874 | denotes | ms |
T17 | 1241-1245 | http://purl.obolibrary.org/obo/UBERON_0003101 | denotes | male |
T18 | 1241-1245 | http://www.ebi.ac.uk/efo/EFO_0000970 | denotes | male |
T19 | 1346-1348 | http://purl.obolibrary.org/obo/CLO_0007874 | denotes | ms |
T20 | 1456-1457 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T21 | 1737-1738 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 26-44 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T2 | 61-70 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T3 | 71-80 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T4 | 84-96 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T5 | 162-167 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T6 | 379-397 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T7 | 399-401 | Chemical | denotes | HY | http://purl.obolibrary.org/obo/CHEBI_74059|http://purl.obolibrary.org/obo/CHEBI_5801 |
T9 | 408-417 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T10 | 418-427 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T11 | 429-431 | Chemical | denotes | RD | http://purl.obolibrary.org/obo/CHEBI_73812 |
T12 | 436-448 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T13 | 450-452 | Chemical | denotes | AZ | http://purl.obolibrary.org/obo/CHEBI_2955 |
T14 | 598-600 | Chemical | denotes | HY | http://purl.obolibrary.org/obo/CHEBI_74059|http://purl.obolibrary.org/obo/CHEBI_5801 |
T16 | 601-603 | Chemical | denotes | RD | http://purl.obolibrary.org/obo/CHEBI_73812 |
T17 | 682-684 | Chemical | denotes | HY | http://purl.obolibrary.org/obo/CHEBI_74059|http://purl.obolibrary.org/obo/CHEBI_5801 |
T19 | 685-687 | Chemical | denotes | AZ | http://purl.obolibrary.org/obo/CHEBI_2955 |
T20 | 711-714 | Chemical | denotes | ECG | http://purl.obolibrary.org/obo/CHEBI_70255 |
T21 | 820-822 | Chemical | denotes | HY | http://purl.obolibrary.org/obo/CHEBI_74059|http://purl.obolibrary.org/obo/CHEBI_5801 |
T23 | 823-825 | Chemical | denotes | RD | http://purl.obolibrary.org/obo/CHEBI_73812 |
T24 | 826-831 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T25 | 842-844 | Chemical | denotes | HY | http://purl.obolibrary.org/obo/CHEBI_74059|http://purl.obolibrary.org/obo/CHEBI_5801 |
T27 | 845-847 | Chemical | denotes | AZ | http://purl.obolibrary.org/obo/CHEBI_2955 |
T28 | 848-853 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T29 | 981-983 | Chemical | denotes | HY | http://purl.obolibrary.org/obo/CHEBI_74059|http://purl.obolibrary.org/obo/CHEBI_5801 |
T31 | 984-986 | Chemical | denotes | RD | http://purl.obolibrary.org/obo/CHEBI_73812 |
T32 | 1019-1021 | Chemical | denotes | HY | http://purl.obolibrary.org/obo/CHEBI_74059|http://purl.obolibrary.org/obo/CHEBI_5801 |
T34 | 1022-1024 | Chemical | denotes | AZ | http://purl.obolibrary.org/obo/CHEBI_2955 |
T35 | 1241-1245 | Chemical | denotes | male | http://purl.obolibrary.org/obo/CHEBI_30780 |
T36 | 1441-1446 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T37 | 1533-1542 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T38 | 1543-1552 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T39 | 1556-1568 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T40 | 1709-1714 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 1468-1490 | Phenotype | denotes | ventricular arrhythmia | http://purl.obolibrary.org/obo/HP_0004308 |
T2 | 1662-1673 | Phenotype | denotes | arrhythmias | http://purl.obolibrary.org/obo/HP_0011675 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-135 | Sentence | denotes | Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection. |
T2 | 136-149 | Sentence | denotes | INTRODUCTION: |
T3 | 150-314 | Sentence | denotes | Most of the drugs associations that have been used to treat patients with SARS-CoV-2 infection increase the risk of prolongation of the corrected QT interval (QTc). |
T4 | 315-325 | Sentence | denotes | OBJECTIVE: |
T5 | 326-471 | Sentence | denotes | To evaluate the effects of an association therapy of hydroxychloroquine (HY) plus ritonavir/darunavir (RD) or azithromycin (AZ) on QTc intervals. |
T6 | 472-480 | Sentence | denotes | METHODS: |
T7 | 481-688 | Sentence | denotes | At the beginning of COVID-19 pandemic patients admitted to our hospital were treated with the empiric association of HY/RD; one week later the therapeutic protocol was modified with the combination of HY/AZ. |
T8 | 689-769 | Sentence | denotes | Patients underwent an ECG at baseline, then 3 and 7 days after starting therapy. |
T9 | 770-855 | Sentence | denotes | We prospectively enrolled 113 patients (61 in the HY/RD group-52 in the HY/AZ group). |
T10 | 856-864 | Sentence | denotes | RESULTS: |
T11 | 865-1055 | Sentence | denotes | A significant increase in median QTc was reported after seven days of therapy in both groups: from 438 to 452 ms in HY/RD patients; from 433 to 440 ms in HY/AZ patients (p = 0.001 for both). |
T12 | 1056-1105 | Sentence | denotes | 23 patients (21.2%) had a QTc > 500 ms at 7 days. |
T13 | 1106-1424 | Sentence | denotes | The risk of developing a QTc > 500 ms was greater in patients with prolonged baseline QTc values (≥ 440 ms for female and ≥ 460 ms for male patients) (OR 7.10 (95% IC 1.88-26.81); p = 0.004) and in patients with an increase in the QTc > 40 ms 3 days after onset of treatment (OR 30.15 (95% IC 6.96-130.55); p = 0.001). |
T14 | 1425-1491 | Sentence | denotes | One patient per group suffered a malignant ventricular arrhythmia. |
T15 | 1492-1503 | Sentence | denotes | CONCLUSION: |
T16 | 1504-1628 | Sentence | denotes | Hydroxychloroquine with both ritonavir/darunavir or azithromycin therapy significantly increased the QTc-interval at 7 days. |
T17 | 1629-1762 | Sentence | denotes | The risk of developing malignant arrhythmias remained relatively low when these drugs were administered for a limited period of time. |
hydroxychloroquine
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 1468-1490 | Phenotype | denotes | ventricular arrhythmia | http://purl.obolibrary.org/obo/HP_0004308 |
T2 | 1662-1673 | Phenotype | denotes | arrhythmias | http://purl.obolibrary.org/obo/HP_0011675 |